New eye injection trial aims to halt blinding disease
NCT ID NCT06164587
Summary
This study is testing the safety and early effectiveness of an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Up to 30 participants will receive injections of the drug into the eye and be monitored for 26 weeks. The main goals are to see if the treatment is safe and if it can slow the growth of the damaging eye lesions or help preserve vision.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hilton Head Retina Institute
Hilton Head, South Carolina, 29926-2277, United States
-
Loma Linda University
Loma Linda, California, 92354, United States
-
Ophthalmology LTD
Sioux Falls, South Dakota, 57108, United States
-
Oregon Eye Consultants, Cascade Medical Research
Eugene, Oregon, 97401, United States
-
Southeastern Retina Associates
Hixson, Tennessee, 37343, United States
-
Southeastern Retina Associates
Bristol, Virginia, 24201, United States
-
The Maine Eye Center
Portland, Maine, 04101, United States
-
University of Kentucky Advanced Eye Care
Lexington, Kentucky, 40508, United States
-
Vistar Eye Center
Roanoke, Virginia, 24019, United States
Conditions
Explore the condition pages connected to this study.